1 seventy-eight patients (52.4%) randomized to etelcalcetide achieved more than 50% reduction in PTH co

2 49 and 384 pg/mL vs 820 and 897 pg/mL in the etelcalcetide and placebo groups, respectively, in trial

3 e efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet.

4 ary efficacy end point was noninferiority of etelcalcetide at achieving more than a 30% reduction fro

5 severe secondary hyperparathyroidism, use of etelcalcetide compared with placebo resulted in greater

6 ls A and B, respectively, patients receiving etelcalcetide had more muscle spasms (12.0% and 11.1% vs

7                                              Etelcalcetide intravenously and oral placebo (n = 340) o

8                Intravenous administration of etelcalcetide (n = 503) or placebo (n = 513) after each

9 e the effect of the intravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concent

10 ve clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs IV

11 f 340 patients (68.2%) randomized to receive etelcalcetide was -10.5% (95% CI, -17.5% to -3.5%, P for

12                                              Etelcalcetide was noninferior to cinacalcet on the prima

13 re secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet in reducing

14                       Patients randomized to etelcalcetide were significantly more likely to achieve

15                       Patients randomized to etelcalcetide were significantly more likely to achieve